Literature DB >> 12778778

Influence of tumor grade on expression of CA 125 in serum and tissue in patients with serous ovarian carcinoma.

Igor But1.   

Abstract

OBJECTIVE: The factors affecting CA 125 expression in tissue in serous carcinoma are not well known. The aim of our study was to establish how CA 125 expression in serum and tissue is affected by DNA-ploidy, proliferative activity of tumor cells, tumor grade and the stage of the disease. STUDY
DESIGN: This retrospective study included 50 patients with ovarian carcinoma. The serum CA 125 level was determined preoperatively in all patients. Antigen expression in tissue was confirmed using CA 125-immunohistochemistry. Suspensions of nuclei were prepared from tissue sections and DNA-ploidy was determined using flow cytometry. Data were analyzed using nonparametric statistics and multivariant analysis.
RESULTS: The average level of serum CA 125 was 674.5 U/ml and was significantly higher in advanced (p = 0.00044) and dedifferentiated (p = 0.00055) tumors and in tumors with a higher S-phase fraction (SPF) (p = 0.011). The mean percent of CA 125-positive cells in tissue was 38.3. CA 125 immunostaining was not related to tumor grade or DNA-ploidy. A positive CA 125 test in both tissue and serum was confirmed in 33 cases (66%). The correlation between expression of CA 125 in tissue and serum was weak (r = 0.28) and nonsignificant (p = 0.052).
CONCLUSIONS: No reliable conclusions could be drawn on the influence of the studied parameters on expression of CA 125 in tissue and serum. The effect of tumor grade seems to be the strongest influence, particularly on CA 125 expression in serum, but it is not independent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12778778     DOI: 10.1007/bf03040324

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  20 in total

1.  DNA-ploidy as an independent prognostic factor in patients with serous ovarian carcinoma.

Authors:  I But; B Gorisek
Journal:  Int J Gynaecol Obstet       Date:  2000-12       Impact factor: 3.561

Review 2.  Flow cytometric DNA analysis of human solid tumors: a review of the interpretation of DNA histograms.

Authors:  R P Wersto; R L Liblit; L G Koss
Journal:  Hum Pathol       Date:  1991-11       Impact factor: 3.466

3.  Immunohistochemical analysis of CA125, CA19-9, and Ki-67 in stage III or IV endometriosis: positive correlation between serum CA125 level and endometriotic epithelial cell proliferation.

Authors:  T Toki; J Kubota; X Lu; K Nakayama
Journal:  Acta Obstet Gynecol Scand       Date:  2000-09       Impact factor: 3.636

4.  Pelvic inflammatory disease. Correlation of severity with CA-125 levels.

Authors:  K H Moley; L S Massad; D G Mutch
Journal:  J Reprod Med       Date:  1996-05       Impact factor: 0.142

5.  Immunohistochemical detection of CA-125 and carcinoembryonic antigen in ovarian tumors in relation to corresponding preoperative serum levels.

Authors:  B. Tholander; A. Lindgren; A. Taube; S. Sténson
Journal:  Int J Gynecol Cancer       Date:  1992-09       Impact factor: 3.437

6.  Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer.

Authors:  I But; B Gorisek
Journal:  Gynecol Oncol       Date:  1996-11       Impact factor: 5.482

7.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.

Authors:  D W Hedley; M L Friedlander; I W Taylor; C A Rugg; E A Musgrove
Journal:  J Histochem Cytochem       Date:  1983-11       Impact factor: 2.479

8.  CA 125 secretion by peritoneal mesothelial cells.

Authors:  A M Zeillemaker; H A Verbrugh; A A Hoynck van Papendrecht; P Leguit
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

Review 9.  What do CA 125 and other antigens tell us about ovarian cancer biology?

Authors:  C E Welander
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1992

10.  Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas.

Authors:  C C van Niekerk; O C Boerman; F C Ramaekers; L G Poels
Journal:  Am J Pathol       Date:  1991-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.